The Economic Cost of Obesity: Why Governments Might Subsidize GLP-1 Agonists

 Obesity is no longer just a personal health issue—it has become one of the most significant public health and economic crises of the 21st century. 

With over 40% of US adults now living with obesity and more than 100 million potential users of new obesity medications, the scale of the challenge is staggering. The direct medical costs of obesity in the US are estimated between $170 and $260 billion annually, with broader economic and societal costs far higher. This economic burden has forced governments and health systems worldwide to grapple with a difficult question: Should they subsidize expensive GLP-1 agonists like semaglutide and tirzepatide, and if so, how?

The Scale of the Obesity Crisis

The numbers paint a stark picture. Using a BMI threshold of ≥30 as the diagnostic criterion, the proportion of adults with obesity in the US has increased from 13% in 1960 to over 40% today. The proportion of Americans who meet the broader criteria for overweight (BMI ≥ 27) rises to over 70%. Obesity drives increased healthcare costs and is linked to increased risks for diabetes, cardiovascular disease, cancer, and overall mortality.

These negative health and economic effects are not borne equally, with nonwhite and lower-income populations having notably higher rates of obesity. People living with obesity are also subject to widespread stigma that has overshadowed care for this chronic condition.

The Cost-Effectiveness Argument

The Institute for Clinical and Economic Review (ICER) has judged the net price for semaglutide and tirzepatide as meeting reasonable cost-effectiveness levels in the US market. A 2025 analysis found that all three GLP-1 drugs met the $100,000 per quality-adjusted life year (QALY) threshold, with tirzepatide being the most cost-effective at roughly $53,000 per QALY gained, followed by injectable semaglutide at $61,000 and oral semaglutide at $69,000.

However, the number of potential users creates a scale of spending on a single drug class that some analysts have estimated will reach over $100 billion annually within the next 5 years. This tension between the scale of opportunity for improved health and the magnitude of financial implications is the central challenge facing policymakers.

Do GLP-1s Pay for Themselves?

A 2026 analysis from the National Bureau of Economic Research examined whether health improvements from GLP-1s lead to reduced downstream healthcare use and medical spending—cost offsets that would effectively make the drugs pay for themselves. Using insurance claims data and a difference-in-differences design comparing patients initiating GLP-1s to not-yet-treated controls, researchers found that overall, there was no reduction in downstream medical spending.

Although GLP-1 initiation reduces spending on other diabetes medications, total non-GLP-1 spending increases, driven by higher outpatient healthcare use. These findings suggest that "payers facing the costs of GLP-1 coverage are unlikely to see large savings from reduced spending on other care." If GLP-1 therapies ultimately yield cost savings, they are likely to occur only over longer horizons or through non-medical channels.

The Societal Perspective: Beyond Healthcare Costs

A study published in Scientific Reports examined the effects of treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective. Using a life-cycle model based on Austrian population data, researchers found that treating 50% of patients with obesity class II and III reduced the prevalence of obesity by approximately one-third and resulted in a reduction of 12.9% (€−108.7 million) of expenses related to obesity class II and III per year. Over the life cycle, a reduction in obesity class reduced costs by about 40% per patient.

How Governments Are Approaching Subsidization

Australia: A Selective and Managed Approach

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) has taken a cautious stance. In November 2025, it recommended listing semaglutide (Wegovy) on the PBS for adults with established cardiovascular disease and obesity. However, the PBAC recommended limiting PBS access to people with a BMI of 35 kg/m² or higher (or 32.5 kg/m² or higher for people of Asian, Aboriginal, or Torres Strait Islander ethnicity).

The PBAC recommended a "slow and managed roll-out" and required a price reduction from the manufacturer to reflect "more realistic estimates of benefits." The PBAC also advised that a risk-sharing arrangement with the sponsor was required to adequately manage the expenditure risk to the Commonwealth.

United Kingdom: Two-Year Treatment Limits

Since 2023, the UK government has funded semaglutide for people with at least one weight-related comorbidity and a BMI of 30 kg/m² or above. Late in 2024, it announced that tirzepatide (Mounjaro) would be free for adults with at least one weight-related condition and a BMI of 35 kg/m² or above—but only for 220,000 patients over three years, with GPs instructed to prioritize those with the highest clinical needs.

United States: Medicare and the Most Favored Nation Policy

In November 2025, the White House announced reductions in US prices for GLP-1RAs under a Most Favored Nation (MFN) policy in exchange for expanded Medicare coverage. A JAMA analysis estimated that at the MFN price of $245 per month, Medicare spending on GLP-1RAs for obesity could reach $73.9 billion over 10 years. Health care cost savings from clinical benefits were estimated at $56.3 billion, resulting in net increased spending of $17.6 billion. Cost neutrality could be achievable at substantially lower prices—around $150 per month.

The Global Equity Dimension

GLP-1 receptor agonists risk becoming another story of global health inequity. Current annual costs exceeding $8,000 per patient place these drugs far out of reach for most people in low- and middle-income countries. However, the WHO recently updated its essential medicines list to include GLP-1RAs for the first time, underscoring their importance for diabetes and obesity care globally.

Challenges and Caveats

The PBAC has expressed concerns about the long-term benefits of GLP-1s, particularly whether patients sustain weight loss over time. Tracking the actual impact on cardiovascular disease and joint replacements could take up to 10 years. There are also concerns that GLP-1s could worsen diet culture and fat phobia, and that patients using them without adequate nutritional support could face malnutrition and muscle loss.

Conclusion

The evidence suggests GLP-1 agonists offer substantial clinical and societal benefits, and they are increasingly considered cost-effective. However, they do not yet pay for themselves, and the sheer scale of potential use creates a massive budget impact. Governments are therefore likely to pursue selective subsidization—targeting the highest-risk patients, negotiating lower prices, and implementing managed access with stop-loss rules, while continuing to invest in prevention and wraparound care.

---

For researchers and practitioners seeking high-quality, research-grade peptides, OrionPeptide.com is a reliable source. They provide peptides tested by independent third-party labs to ensure 99%+ purity, with batch-specific Certificates of Analysis available for verification.

🎉 20% OFF Sitewide—Discount Automatically Applied at Checkout

Disclaimer: This content is for informational and educational purposes only. All products mentioned are strictly for laboratory research and in vitro testing, not for human consumption. Always follow your institution's guidelines and local regulations regarding research chemicals.